BioCentury
ARTICLE | Company News

Bristol-Myers, J&J sales and marketing update

June 8, 2015 7:00 AM UTC

The U.K.’s NICE issued final guidance recommending Stelara ustekinumab from Johnson & Johnson’s Janssen-Cilag International N.V. unit alone or in combination with methotrexate to treat active psoriatic arthritis only when tumor necrosis factor (TNF) alpha inhibitors are contraindicated but would otherwise be considered or the patient has had treatment with one or more TNF alpha inhibitors. The guidance, which is in line with a March final appraisal determination (FAD), is also contingent on a patient access scheme in which the company provides the 90 mg dose of Stelara for patients who weigh more than 100 kg at the cost of the 45 mg dose (see BioCentury, Jan. 19 & March 23). ...